Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized double-blind placebo-controlled study of NWRD09 in HPV16-positive cervical HSIL
CTR20262557Phase 2Active
- Sponsor
- Newish Technology (Beijing) Co., Ltd.
- Start
- Jul 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of NWRD09 in cervical intraepithelial neoplasia (CIN), HPV16 infection (HPV16), sponsored by Newish Technology (Beijing) Co., Ltd.. Started Jul 2026; status: active.
02
Drugs
NWRD09
03
Conditions
cervical intraepithelial neoplasia (CIN)HPV16 infection (HPV16)
Beyond the preview
Go deeper on CTR20262557.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262557.